Next Article in Journal
High Intensity Focused Ultrasound for Treatment of Bone Malignancies—20 Years of History
Next Article in Special Issue
Phytochemical Compounds and Anticancer Activity of Cladanthus mixtus Extracts from Northern Morocco
Previous Article in Journal
The Role of Age and Comorbidities in Esophagogastric Cancer Chemoradiation of the Frail Elderly (>70 Years): An Analysis from a Tertiary High Volume-Center
Previous Article in Special Issue
Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy
 
 
Article
Peer-Review Record

Targets, Mechanisms and Cytotoxicity of Half-Sandwich Ir(III) Complexes Are Modulated by Structural Modifications on the Benzazole Ancillary Ligand

Cancers 2023, 15(1), 107; https://doi.org/10.3390/cancers15010107
by M. Isabel Acuña 1,†, Ana R. Rubio 2,3,†, Marta Martínez-Alonso 2,*, Natalia Busto 2,4,*, Ana María Rodríguez 5, Nerea Davila-Ferreira 1, Carl Smythe 3, Gustavo Espino 2, Begoña García 2 and Fernando Domínguez 1
Reviewer 1:
Reviewer 2:
Cancers 2023, 15(1), 107; https://doi.org/10.3390/cancers15010107
Submission received: 16 November 2022 / Revised: 13 December 2022 / Accepted: 19 December 2022 / Published: 24 December 2022
(This article belongs to the Special Issue Advances in Anticancer Drugs and Pharmacotherapy of Cancer)

Round 1

Reviewer 1 Report

Please see the attached file.

Comments for author File: Comments.docx

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Dear Authors, 

it was very interesting to review the presented manuscript demonstrating tremendous research efforts. 
The review summary and questions are given in the attached file.

Best regards.

Comments for author File: Comments.docx

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

Dear Authors,

Thank you very much for the responses to the previous questions and the edits in the revised manuscript. It is very much appreciated to see that all questions and comments have been addressed.

 

Some minor questions remain:

The explanation given as of line 984 refers to an article (reference 107), but not to actual data from the own study. Also other factors influence the efficacy of a drug on the primary tumor and not on the metastasis. The authors may reconsider and add potential other reasons, why tumor cells in the mediastinal nodes are less sensitive (biodistribution, cell-cell interactions, matrix in the nodes, etc.).

 

What is the reason of having used Balb/c mice for the bio distribution and nude mice for the orthotopic lung cancer model? Nude mice may have been used for both. It would be appreciated if the authors may give a statement in the manuscript.

 

The graph of the tumor growth in the response letter represents the tumor growth as % tumor growth and an increase of approx. 5000 % can be seen by day 33. Does the % value represent the total fluorescence measure without a further discrimination of the primary tumor and the metastatic tumor? Would the authors mind to show an IVIS image to demonstrate the way this has been calculated? In addition, may the authors explain what happens from day 28 to day 35? The error bars indicate that some tumors disappeared while others increased by a 2-fold.

 

In the second graph showing the weight of the mice, it appears that mice gain weight at the end of experiment. Does the weight gain (day 33-35) result from the tumor?

What is the actual tumor size and weight after dissection?

 

It would be appreciated if the authors may add the statement of the necropsy analysis in the manuscript.

 

My apologies for having it phrased not accurately enough. It was not meant to measure mitochondrial activity in vivo, but perform certain measures after the termination when the tissues were extracted. Would it be possible for the authors to still perform certain analysis (i.e. visualization of mitochondria) in the tissues that were removed from the euthanized animals.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop